Article | April 14, 2022

Outsourcers Are Feeling Uneasy About Continuity of Supply

Source: ISR Reports

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

As the COVID-19 pandemic continues to stymie travel, in-person meetings, and on-site work, the complications felt in the outsourced manufacturing space appear to be increasing. Concerns are particularly strong among drug product outsourcers for both small molecules and biologics. In fact, when reviewing the responses from Industry Standard Research’s annual CDMO Benchmarking research, where ISR has asked about how the pandemic has impacted outsourced manufacturing activities each of the past two years, the data show proportionally more outsourcers were impacted in 2021 than in 2020. Among small molecule drug product outsourcers, 40% confirmed their company experienced manufacturing complications tied to the pandemic during 2020. One year later, 57% of small molecule drug product outsourcers said the same, an increase of 17 percentage points. On the biologic side of drug product manufacturing, a year ago 51% of respondents confirmed manufacturing complications as a result of the pandemic. In 2021, that figure increased by eight percentage points to 59% of respondents.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online